arc-1779
Nucleic acidexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00432770)
Timeline
Indications
Mechanism of action
- von Willebrand factorINHIBITOR
VWF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- arc1779
- arc1779
- arc 1779
- arc 1779
- arc-1779
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00742612 | Phase 2 | Feb 1, 2009 | Archemix Corp., University of London |
| NCT00726544 | Phase 2 | Dec 1, 2008 | Archemix Corp. |
| NCT00694785 | Phase 2 | Oct 1, 2008 | Archemix Corp. |
| NCT00632242 | Phase 2 | Jan 1, 2008 | Archemix Corp. |
| NCT00432770 | Phase 1 | Dec 1, 2006 | Archemix Corp. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Archemix Corp. | For profit | 5 | 5 | 2 | 2006 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1